Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
27.33 | 29.31 | 26.25 | 28.66 |
P/S ratio |
8.54 | 9.66 | 9.29 | 10.01 | |
P/FCF ratio |
30.00 | 36.30 | 30.58 | 33.20 | |
P/Operating CF |
80.64 | 232.78 | 79.45 | 111.98 | |
P/B ratio |
5.78 | 6.21 | 5.86 | 6.22 | |
Price to Tangible BV |
6.34 | 6.76 | 6.35 | 6.72 | |
EV/Sales |
8.02 | 9.13 | 8.71 | 9.40 | |
EV/EBITDA |
22.42 | 24.99 | 21.72 | 23.68 | |
EV/Operating CF |
25.29 | 30.16 | 25.10 | 27.57 | |
EV/FCF |
28.17 | 34.29 | 28.68 | 31.18 | |
Quick Ratio |
1.84 | 2.24 | 2.38 | 2.54 | |
Current Ratio |
2.36 | 2.90 | 3.02 | 3.19 | |
Net Debt/EBITDA |
(5.07) | (5.24) | (6.07) | (6.02) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.49 | |
Operating CF/Net income |
1.15 | 0.42 | 1.38 | 1.02 | |
Capex/Depreciation |
(1.89) | (2.68) | (2.39) | (1.99) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
31.78% | 30.52% | 32.19% | 29.81% | |
Selling, General and Administrative Expense of Revenue |
14.47% | 15.27% | 16.53% | 17.46% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
6.34% | 4.94% | 5.57% | 5.11% | |
Graham Net Nets |
0.03 | 0.04 | 0.04 | 0.04 | |
Graham Number |
147.81 | 159.40 | 170.77 | 176.41 | |
Earnings Yield |
3.66% | 3.41% | 3.81% | 3.49% | |
Free Cash Flow Yield |
3.33% | 2.76% | 3.27% | 3.01% | |
Revenue per Share |
12.04 | 12.48 | 11.75 | 13.14 | |
Operating CF per Share |
4.86 | 1.95 | 5.62 | 4.44 | |
Capex per Share |
(0.40) | (0.58) | (0.52) | (0.44) | |
Free Cash Flow per Share |
4.46 | 1.36 | 5.10 | 3.99 | |
Cash per Share |
24.60 | 25.84 | 28.52 | 30.95 | |
Shareholders Equity per Share |
67.76 | 73.00 | 76.20 | 79.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
67.76 | 73.00 | 76.20 | 79.81 | |
Free Cash Flow |
1,139.60 | 348.60 | 1,294.70 | 1,013.20 | |
Working Capital |
6,094.30 | 7,339.80 | 7,849.70 | 8,605.80 | |
Capital Expenditures |
(101.80) | (149.40) | (133.40) | (112.20) | |
Net Current Asset Value |
3,026.10 | 4,223.80 | 4,607.80 | 5,368.30 | |
EV/EBIT |
23.54 | 26.24 | 22.73 | 24.78 | |
Capex to Sales |
0.03 | 0.05 | 0.04 | 0.03 | |
Net Profit Margin |
35.20% | 37.34% | 34.53% | 32.99% | |
Price to Operating Income |
25.07 | 27.78 | 24.24 | 26.38 | |
| Other line items | |||||
Average Receivables |
1,848.50 | 1,831.10 | 1,900.60 | 2,013.90 | |
Average Payables |
408.05 | 437.35 | 467.15 | 435.90 | |
Average Inventory |
1,353.30 | 1,446.10 | 1,563.20 | 1,632.20 | |
Average Assets |
23,551.25 | 24,088.10 | 24,682.45 | 25,730.00 | |
Average Common Equity |
16,474.85 | 17,537.70 | 17,929.10 | 18,711.65 |
Columns are period end dates